Earnings ·
Opus Genetics reports Q3 net loss of $46.5M and triggers milestone payment from Viatris
IRDOpus Genetics, Inc.
Opus Genetics reported a net loss of $46.5 million, or $0.46 per share, for the third quarter ended September 30, 2026, compared to a $17.5 million loss in the prior-year period. The widening loss was driven by an $8.1 million increase in research and development expenses and a $28.6 million non-cash charge from fair value changes in financial instruments. Revenue declined to $1.1 million from $3.1 million as R&D reimbursement costs rose. The company also announced that FDA approval of phentolamine ophthalmic solution for presbyopia triggered a regulatory milestone payment from partner Viatris. Pipeline updates include the completion of dosing for OPGx-BEST1 Cohort 2, full enrollment in the Phase 3 OPGx-LCA5 trial, and IND clearance for OPGx-RDH12. Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases.